Quarterly ResultAug 4, 2026, 04:16 PM
Ultragenyx Q2 Revenue $214M; Reaffirms 2026 Guidance
AI Summary
Ultragenyx Pharmaceutical Inc. reported record second quarter 2026 total revenue of $214 million, driven by Crysvita and Dojolvi sales. The company reaffirmed its full-year 2026 total revenue guidance of $730 million to $760 million and its commitment to achieving profitability in 2027. Ultragenyx also highlighted significant upcoming catalysts, including two PDUFA dates for DTX401 and UX111, and pivotal data from the GTX-102 Phase 3 Aspire study expected in the second half of 2026. Net loss for the quarter improved to $92 million, or $0.90 per share.
Key Highlights
- Q2 2026 total revenue was $214 million, highest quarterly revenue in company history.
- Q2 2026 Crysvita revenue was $156 million; Dojolvi revenue was $27 million.
- Reaffirmed full-year 2026 total revenue guidance of $730 million to $760 million.
- Reaffirmed path to profitability in 2027.
- Net loss for Q2 2026 was $92 million, or $0.90 per share.
- DTX401 (GSDIa) BLA PDUFA action date is August 23, 2026.
- UX111 (MPS IIIA) BLA PDUFA action date is September 19, 2026.
- GTX-102 Phase 3 Aspire study data for Angelman syndrome expected September/October.
Price Impact
More from RARE